10x Genomics CFO Taich Adam Sells Shares

What Happened

• Taich Adam, Chief Financial Officer of 10x Genomics (TXG), reported three open-market sales on September 9, 2026: 1,206 shares at a weighted average $63.68 ($76,795), 31,428 shares at $64.31 ($2,021,125), and 13,754 shares at $65.26 ($897,550). Total shares sold = 46,388 for aggregate proceeds of $2,995,470. These transactions are coded as sales (S).

Key Details

• Transaction date: September 9, 2026; Form 4 filed September 11, 2026 (timely — within the two-business-day reporting window).
• Reported prices (weighted averages) and ranges per footnotes:
  • 1,206 shares: weighted avg $63.68; trades ranged $63.67–$63.83 (F2).
  • 31,428 shares: weighted avg $64.31; trades ranged $64.01–$64.87 (F3).
  • 13,754 shares: weighted avg $65.26; trades ranged $64.88–$65.875 (F4).
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted June 10, 2026 (F1).
• Shares owned after the transactions are not specified in the supplied filing.

Context

• These were preplanned sales under a 10b5-1 plan, which typically indicate scheduled disposition rather than an ad hoc decision based on new company information. Sales (S) are generally less informative about insider sentiment than purchases. The footnotes state the seller will provide detailed breakdowns of individual trade prices upon request to the SEC, the issuer, or a security holder.